아지오 파마슈티컬스(AGIO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $33.07 (-1.61%), 시가총액 $1.71B, 52주 최저~최고 $22.34 ~ $45.49.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator
아지오 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아지오 파마슈티컬스의 현재 주가는 $33.07 (-1.61%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아지오 파마슈티컬스의 시가총액은 약 $1.71B입니다.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an